Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: Cancer Prev Res (Phila). 2010 Mar 23;3(4):438–446. doi: 10.1158/1940-6207.CAPR-09-0194

Figure 2.

Figure 2

MUC1-specific immune responses in vaccinated versus control MUC1+/IL-10−/− mice. (A) MUC1-specific antibodies in serum of untreated (n=6), adjuvant treated (n=4), and vaccinated (n=7) mice. IgM isotype, top panel; IgG isotype, bottom panel; Optical Density (O.D.) measured by ELISA at 450 nm. Serum samples were diluted 1:50. P value was determined by unpaired two-tailed Student’s t test. (B) Splenocytes from untreated, adjuvant treated, or vaccinated MUC1+/IL-10−/− mice were stained with MUC1 peptide loaded H2Kb-Ig dimer. Representative dot plots from two independent experiments. (C) Results of standard 51Cr release assay at an effector:tumor cell (E:T) ratio of 50:1. Effector cells are pooled lymph node (LN) from two mice per group. Targets are RMA (H2Kb) or RMA-MUC1 (H2Kb), transfected with human MUC1 cDNA. (D) Immunostaining (hematoxylin counterstained) of colon sections with anti-MUC1 antibodies. Scale bar, 50μm.